We aim to determine the association between iron status and metabolic syndrome (MetS) during menopause. Records of 1,069 premenopausal and 703 postmenopausal Korean women were retrieved from the database of the Korean National Health and Nutrition Examination Survey (KNHANES V 2012) and analysed. The association between MetS and iron status was performed using multivariable-adjusted analyses, subsequently develop a prediction model for MetS by margin effects. We found that the risk of iron depletion among postmenopausal women was lower than premenopausal women (PR=0.813, 95% CI: 0.668–0.998, p=0.038). The risk of MetS was 2.562-fold lower among premenopausal women with than without iron depletion (PR=0.390, 95% CI: 0.266–0.571, p<0.001). In contrast, the risk of MetS tended to be higher among postmenopausal women with than without iron depletion (PR=1.849, 95% CI: 1.406–2.432, p<0.001). When the serum ferritin levels increased, the risk of the MetS increased in both premenopausal women and postmenopausal women. The margin effects showed that an increase in serum haemoglobin and ferritin was associated with an increase in the risk of MetS according to menopausal status and age group. Therefore, ferritin is the most validated and widely used iron marker, could be a potential clinical value in predicting and monitoring MetS during menopause. Further prospective or longitudinal studies, especially, clinically related studies on menopause and iron status are needed to clarify the causality between serum ferritin levels and MetS that could offer novel treatments for MetS.